Eastern Cooperative Oncology Group:

IBCSG2402- A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer

You can learn more about this trial by viewing a short informational video featuring Dr. Nancy Davidson:

• IBCSG2402 Real Media Video
• IBCSG2402 Windows Media Video

Click here for a list of institutions participating in this trial

Note to institutions: Use of these videos for patient education requires approval of your institution's IRB.

Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

This randomized phase III trial is studying ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

It is not known at this time whether there is any benefit that would result from ovarian suppression with either tamoxifen or exemestane. This is the question that we hope will be answered by this trial.

You can learn more about breast cancer treatment options by visiting these web sites:

• National Cancer Institute Breast Cancer Infomration
• Y-ME National Breast Cancer Organization For The Cure

Information about cancer clinical trials can be found at:

National Cancer Institute Clinical Trials Information

CancerTrialsHelp - Coalition of Cancer Cooperative Groups